203564-57-2Relevant articles and documents
Identification and initial structure-activity relationships of (R)-5- (2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors
Holladay, Mark W.,Wasicak, James T.,Lin, Nan-Horng,He, Yun,Ryther, Keith,Bannon, Anthony W.,Buckley, Michael J.,Kim, David J. B.,Decker, Michael W.,Anderson, David J.,Campbell, Jeffrey E.,Kuntzweiler, Theresa A.,Donnelly-Roberts, Diana L.,Piattoni-Kaplan, Marietta,Briggs, Clark A.,Williams, Michael,Arneric, Stephen P.
, p. 407 - 412 (1998)
New members of a previously reported series of 3-pyridyl ether compounds are disclosed as novel, potent analgesic agents acting through neuronal nicotinic acetylcholine receptors. Both (R)-2-chloro-5-(2- azetidinylmethoxy)pyridine (ABT-594, 5) and its S-enantiomer (4) show potent analgesic activity in the mouse hot-plate assay following either intraperitoneal (ip) or oral (po) administration, as well as activity in the mouse abdominal constriction (writhing) assay, a model of persistent pain. Compared to the S-enantiomer and to the prototypical potent nicotinic analgesic agent (±)-epibatidine, 5 shows diminished activity in models of peripheral side effects. Structure-activity studies of analogues related to 4 and 5 suggest that the N-unsubstituted azetidine moiety and the 2-chloro substituent on the pyridine ring are important contributors to potent analgesic activity.
